DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Intimation on Transcript of the Earnings call conducted on January 25, 202330-01-2023
30-01-2023
Buy Dr. Reddy's Laboratories; target of Rs 4900: Prabhudas Lilladher
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated January 27, 2023.29-01-2023
Buy Dr. Reddy's Laboratories, target of Rs 5460: Sharekhan
Sharekhan is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 5460 in its research report dated January 25, 2023.27-01-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press Release on 'Dr. Reddy''s Laboratories announces the launch of Difluprednate Ophthalmic Emulsion 0.05% in the U.S. Market'.27-01-2023
Dr. Reddy's Laboratories Results Earnings Call for Q3FY23
Conference Call with Dr. Reddy's Laboratories Management and Analysts on Q3FY23 Performance and Outlook. Listen to the full earnings transcript.26-01-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Copies of Newspaper advertisement for the unaudited financial results for quarter and nine months ended December 31, 202226-01-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Form 6-K For The Quarter Ended December 31, 2022, Filed With United States Securities And Exchange Commission.
Intimation regarding filing of Form 6-K for the quarter ended December 31, 2022, filed with United States Securities and Exchange Commission.26-01-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Audio Recording of the Earnings call conducted on January 25, 202326-01-2023
Dr Reddy's Lab Q3 net up 77% at Rs 1,247 cr, revenue from operations jump
Dr Reddy's Laboratories on Wednesday reported a 77 per cent increase in its consolidated net profit at Rs 1,247 crore in the third quarter ended December 31, 2022. The drug firm had reported a net profit of Rs 706 crore in the October-December period of the previous fiscal. Revenue from operations rose to Rs 6,770 crore during the period under review as against Rs 5,320 crore in the year-ago period, Dr Reddy's Laboratories said in a regulatory filing.25-01-2023
DR.REDDY'S LABORATORIES LTD. - 500124 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Issue of Letter of Confirmation in lieu of share certificate(s) reported lost/misplaced25-01-2023